A Case of EML4-ALK Fusion V1 Subtype Lung Adenocarcinoma Detected by RNA-based NGS
10.3779/j.issn.1009-3419.2024.102.23
- VernacularTitle:RNA-based NGS检测EML4-ALK融合V1亚型肺腺癌1例
- Author:
XU YUE
1
;
MU NING
;
LIU MEI
;
WU SHENGNAN
;
MA CHUNHUA
Author Information
1. 300121 天津,天津市人民医院肿瘤诊疗中心
- Keywords:
Lung neoplasms;
Anaplastic lymphoma kinase;
Gene fusion;
Next-generation sequencing;
Immuno-histochemistry;
Targeted therapy
- From:
Chinese Journal of Lung Cancer
2024;27(6):480-484
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the malignant tumor with the highest incidence and mortality rate worldwide.For lung adenocarcinoma,identifying specific gene mutations,fusions,and giving corresponding targeted drugs can greatly improve the survival time of the patients.Among them,anaplastic lymphoma kinase(ALK)fusion occurs in 3％-7％of non-small cell lung cancer(NSCLC).In clinical practice,a variety of detection methods can be used to determine the ALK fusion status,but false negative test results are possible.This paper retrospectively analyzed the diagnosis and treatment of a patient with lung adeno-carcinoma,judged the ALK fusion status by various detection methods.Among them,immunohistochemistry(IHC)(Ventana D5F3),RNA based next-generation sequencing(RNA-based NGS)confirmed positive echinoderm microtubule associated protein like 4(EML4)-ALK fusion,while DNA-based NGS was negative.This paper analyzed the detection methods of ALK fusion,in order to clarify which detection method is the most accurate and simple to choose in different clinical cases and guide the subsequent treatment.
